{"entity":{"id":"nct07342283","kind":"trial","name":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial in triple-negative breast cancer, run by Affiliated Hospital of Nantong University, now recruiting.","summary":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07342283 by Affiliated Hospital of Nantong University, with a registry enrolment figure of 30 participants, started 2026-02-25 and due to reach its primary completion in 2027-12-25. Interventions recorded: Immunotherapy combined with chemotherapy. Conditions listed: Triple Negative Breast Cancer (TNBC). Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07342283","url":"https://clinicaltrials.gov/study/NCT07342283"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07342283","phase":"2","setting":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer","sponsor":"Affiliated Hospital of Nantong University","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07342283/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}